Exciting Abstracts Unveiled for SITC's 40th Annual Meeting

Author: Addison Perry Updated: 10-30-2025 11:16 AM

Discover the Latest in Cancer Immunotherapy from SITC

MILWAUKEE – The Society for Immunotherapy of Cancer (SITC) is thrilled to announce an incredible array of clinical abstract submissions for their forthcoming 40th Anniversary Annual Meeting. This year has seen a remarkable engagement with over 1,300 submissions, featuring a significant number of Late-breaking Abstracts that promise to showcase pioneering research and breakthroughs in immunotherapy.

What to Expect at the Upcoming Annual Meeting

The 40th Anniversary Annual Meeting, set to take place both in-person and virtually, is scheduled for November 5–9. Attendees can look forward to hearing from leading researchers and experts as they unveil cutting-edge data and findings in cancer treatment. "We are excited to incorporate these clinical abstracts into an already impressive lineup of presentations,” said SITC Vice President Sandra Demaria, MD. She emphasized the importance of sharing late-breaking clinical trial data that could revolutionize treatment approaches for cancer patients.

Engaging Presentations That Highlight Innovation

The Late-breaking Abstracts selected for oral presentations aim to deliver the latest insights from interventional clinical trials involving human participants. This focus on new data seeks to enhance discussions around progressive treatment methods and improve patient outcomes. Notably, SITC is on a mission to expedite the approval of 100 novel agents by 2034, viewing this meeting as a vital part of that journey.

Highlighted Late-breaking Abstracts

Among the outstanding Late-breaking Abstracts featured at the annual meeting are the following:

(1316) Monotherapy clinical activity of invikafusp alfa in TMB-H patients from a Phase 1/2 trial by Aurélien Marabelle, MD, PhD.
(1342) Initial safety and efficacy evaluations of mRNA-LNP MT-302 in solid tumors, presented by Rasha Cosman, BSc (Med), MBBS, FRACP.
(1348) Results from the HARMONi-A study comparing ivonescimab plus chemotherapy versus chemotherapy alone in patients with EGFR+ NSCLC by Li Zhang, MD.
(1305) Coformulation of favezelimab with pembrolizumab in neoadjuvant therapy for cSCC by Matteo Carlino, MBBS, PhD, BMedSC, FRACP.
(1346) Study of lenvatinib combined with pembrolizumab in Merkel cell carcinoma by Kenneth Tsai, MD, PhD.
(1327) Evaluation of RP1 plus nivolumab in anti-PD-1-failed melanoma by Trisha Wise-Draper, MD, PhD.
(1328) Efficacy of SSGJ-707, a PD-1/VEGF bispecific antibody, in treating advanced non-small cell lung cancer by Lin Wu, PhD.
(1310) Findings on ILKN421H as monotherapy and combined with pembrolizumab in advanced solid tumors by Haining Huang, PhD.
(1325) Open label phase 2 trial of a DNA plasmid vaccine for advanced melanoma, presented by Nermeen Varawalla, MD, PhD, MBA.
(1336) Final results of Nous-209 monotherapy in Lynch syndrome carriers by Anna Morena D'Alise, PhD.
(1340) Impacts on immune response from lead-in therapy targeting PD1 and/or LAG3 by Lilit Karapetyan, MD.
(1345) Initial phase 1a/1b results of STK-012 combined with pembrolizumab and chemotherapy in NSCLC by Adam Schoenfeld, MD.

When and Where to Attend

The sessions for these Late-breaking Abstracts will be held on November 7 and November 8. Specific timing and locations have been designated in the Gaylord National Resort and Convention Center, while virtual attendees can also engage in these vital discussions. Abstracts from the Regular and Young Investigator Award categories will be available on November 4. Additionally, clinical-only abstracts will be ready for review starting November 7.

About the Society for Immunotherapy of Cancer

SITC represents the forefront of cancer immunotherapy advocacy, dedicated to enhancing treatment outcomes for patients globally. Established in 1984, SITC serves an expansive network of professionals, including scientists, clinicians, and patient advocates, through educational programs aimed at fostering collaboration and innovation. By continuously pushing the boundaries of research and clinical practice, SITC is committed to making significant strides toward curing cancer.

Frequently Asked Questions

What is the significance of the SITC Annual Meeting?

The SITC Annual Meeting serves as a platform for presenting groundbreaking research in cancer immunotherapy, featuring expert discussions and late-breaking clinical trials.

How many abstracts were submitted for the 40th SITC Annual Meeting?

There were over 1,300 abstract submissions this year, highlighting a wide array of innovative research in the field.

What types of abstracts are featured in the meeting?

The meeting features both Regular and Late-breaking Abstracts, focusing on recent advancements in cancer treatment methodologies.

When are key sessions taking place during the event?

Key sessions, including oral presentations of Late-breaking Abstracts, are scheduled for November 7 and 8.

How can I learn more about SITC's initiatives?

Interested individuals can visit SITC's website for detailed information on their ongoing projects and annual meetings.

About The Author

Hello, I'm 30-year-old financial writer and expert Addison Perry, and I love to simplify the intricacies of the financial industry. I've committed myself over the years to deciphering the subtleties of investing techniques and economic trends and converting them into doable guidance that anybody can use. My goal with writings and books is to make money interesting and approachable so that readers may take charge of their financial futures.

My enthusiasm to empowerment and education has propelled me through my career in finance. I write because I think that everyone should be able to make educated financial decisions, and I try to provide that. Regardless of experience level with investing, my work is intended to provide insightful analysis and practical advice to enable you to thrive in the always changing financial environment. I appreciate you traveling with me toward success and financial literacy.

Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.